APOA5 -1131T>C

APOA5 — The Triglyceride Traffic Controller

Apolipoprotein A5 (APOA5) is a liver-secreted protein that acts as a
critical regulator of circulating triglyceride levels. Though present in
plasma at very low concentrations, APOA5 has an outsized effect on fat
clearance | Plasma APOA5 concentrations are 1,000-fold lower than APOA1 yet
exert comparable effects on triglyceride metabolism
by facilitating the activity of lipoprotein lipase (LPL) | The enzyme
anchored to capillary walls that breaks down triglycerides in VLDL and
chylomicrons, the enzyme
responsible for breaking down fat-carrying particles in the bloodstream.
The -1131T>C promoter variant (rs662799) reduces how much APOA5 the liver
produces, weakening this clearance system and allowing triglycerides to
accumulate in circulation.

The Mechanism

The -1131T>C change sits in the promoter region of the APOA5 gene,
approximately 1,131 base pairs upstream of where gene transcription begins.
The C allele (reported as the G allele on the forward genomic strand by
23andMe) impairs ribosomal translation efficiency | In vitro studies show
reduced translational efficiency of mRNA carrying the -1131C allele,
resulting in lower circulating APOA5 protein levels. With less APOA5 available,
LPL activity at the capillary surface is reduced | APOA5 tethers LPL to
heparan sulfate proteoglycans on capillary endothelium and stabilizes the
enzyme, slowing the breakdown of
triglyceride-rich lipoproteins (VLDL and chylomicrons). The result is slower
postprandial triglyceride clearance and higher fasting triglyceride levels.

The effect is additive — each copy of the C (A on forward strand) risk allele
progressively reduces APOA5 expression and raises triglycerides. The variant
is part of the APOA5*2 haplotype | A group of co-inherited APOA5 promoter
variants including rs662799, rs651821, rs2072560, and rs2266788
associated with hypertriglyceridemia susceptibility.

The Evidence

The rs662799 -1131C allele is one of the most replicated genetic
determinants of circulating triglycerides in the human genome.
A meta-analysis of 51,868 participants | Including 46 East Asian studies,
26 European studies, and 19 studies of other ethnic groups
confirmed the C allele raises fasting triglycerides by a weighted mean
difference of 0.30 mmol/L (about 26 mg/dL) and increases metabolic syndrome
risk with an OR of 1.33 (95% CI 1.16–1.53) in the overall population.
In a Hong Kong and Guangzhou Chinese cohort, plasma triglycerides were 36.1%
higher in CC versus TT homozygotes | OR for hypertriglyceridemia ≥1.7 mmol/L
was 2.22 (1.44–3.43) for CC and 1.81 (1.37–2.39) for TC.

The cardiovascular consequences are also significant. A meta-analysis of
49,806 individuals | 21,378 CHD cases and 28,428 controls across 10 ethnic
populations showed the C allele
significantly increases coronary heart disease risk (OR ~1.27 at the allele
level, P < 0.00001), with consistent effects across Chinese, other Asian,
and Caucasian populations.

Practical Actions

The dietary implications of this variant are particularly clear. C allele
carriers appear to have a blunted metabolic response to caloric restriction
and dietary fat improvement | Caucasian obese subjects: TG reduction −19.3
vs −4.2 mg/dL in TT vs C carriers after Mediterranean diet intervention.
In a study of 363 obese Caucasian subjects, TT homozygotes achieved
significant reductions in triglycerides, insulin, and insulin resistance
(HOMA-IR) on a hypocaloric Mediterranean-pattern diet, while C allele
carriers showed no statistically significant improvement on any of these
metabolic parameters.

The fat quality appears to matter more than quantity for C allele carriers.
Specifically, high n-6 polyunsaturated fat intake exacerbates the adverse
effect | Dietary n-6 PUFA intake modulates the APOA5 effect on plasma TG
and remnant lipoprotein concentrations
of the risk allele on triglycerides, suggesting that correcting an
omega-6:omega-3 imbalance is especially important. Increasing EPA and DHA
intake through fatty fish or high-dose fish oil supplements is the most
evidence-based strategy for reducing triglycerides in C allele carriers
whose lifestyle interventions have had limited effect.

Monitoring fasting triglycerides regularly allows early detection of
deterioration before cardiovascular risk accumulates. A fasting TG above
1.7 mmol/L (150 mg/dL) is the threshold for the metabolic syndrome
criterion and a reasonable alert level for C allele carriers to intensify
dietary and supplementation efforts.

Interactions

The rs662799 variant is part of the APOA5*2 haplotype, which co-segregates
with other APOA5 variants — notably rs651821 (-3A>G), rs2072560 (715G>T),
and rs2266788 (1891T>C). These variants are in partial linkage disequilibrium
and collectively define haplotype-level triglyceride risk. Having multiple
APOA5 risk alleles compounds the effect.

APOA5 interacts with the APOE genotype in determining triglyceride clearance
and cardiovascular risk. APOE4 carriers (rs429358) with a concurrent APOA5
risk allele may have amplified dyslipidemia because both proteins affect
VLDL metabolism through overlapping but distinct pathways — APOE governs
VLDL receptor binding while APOA5 controls LPL activity. Individuals with
both variants may benefit most from aggressive triglyceride management.

The rs3135506 variant (APOA5*3, Ser19Trp) is separately and independently
associated with hypertriglyceridemia through a different mechanism (reduced
LPL binding affinity). Carrying both rs662799 and rs3135506 risk alleles
represents a compounded impairment in triglyceride clearance capacity.